Astec LifeSciences reports robust operational recovery in the recent fiscal year, achieving EBITDA break-even and narrowing loss to ₹80.88 Cr on ₹453.22 Cr revenue.

Strategic CDMO business surged 2.5x in H2, supported by new facilities.

A Rights Issue raised ₹249.35 Cr.

New leadership includes a Chairperson and Executive Director.

Labour Code changes impacted financials.